干扰素-γ维持治疗对中晚期卵巢癌无进展生存期及生存率的影响  

Effect of maintenance treatment via interferon-γ on progression-free survival and survival rate of patients with middle and advanced ovarian cancer

作　　者：石占荣 黄冬梅[1] 邓克红[1] 孙欣欣[1] 

机构地区：[1]郑州大学第二附属医院妇产科,河南郑州450014

出　　处：《中国妇幼保健》2015年第33期5895-5897,共3页Maternal and Child Health Care of China

基　　金：河南省科学技术发展计划项目〔112102310505〕;河南省医学科技攻关计划项目〔201203043〕

摘　　要：目的观察干扰素-γ维持治疗对中晚期卵巢癌患者无进展生存期及生存率的影响。方法将中晚期卵巢癌临床缓解期患者52例随机分为观察组25例和对照组27例,对观察组应用干扰素-γ100万u肌内注射,每周3次,应用3个月;对照组停药观察,定期复查。所有患者定期随访两年,比较两组患者的无进展生存期(PFS)及1、2年生存率。结果观察组与对照组的PFS分别为21个月和17个月,两组差异有统计学意义(P<0.05);观察组与对照组1年生存率分别为100.00%(25/25)和92.60%(25/27),2年生存率分别为92.00%(23/25)和74.07%(20/27),两组比较差异均有统计学意义(P<0.05)。观察组总体Ⅲ度不良反应率为16.00%,无Ⅳ度不良反应,无治疗相关死亡事件发生。结论干扰素-γ维持治疗可延长中晚期卵巢癌患者无进展生存期及2年生存率。Objective To observe the effect of maintenance treatment via interferon-γ on progression-free survival （PFS） and survival rate of patients with middle and advanced ovarian cancer. Methods Fifty-two middle and advanced ovarian cancer patients during clinical remission period were randomly divided into observation group （25 cases） and control group （27 cases） . The cases in observation group were treated by intramuscular injection of interferon-γ 1 000 000 U, three times a week for three months ; the cases in control group did not receive drug therapy, and they were reexamined regularly. All the patients were regularly followed up for two years; PFS and oneyear survival rates, two-year survival rates in the two groups were compared. Results PFS in observation group and control group were 21 months and 17 months, respectively, there was statistically significant difference between the two groups （P〈0. 05） ; the one-year survival rates in observation group and control group were 100.00% （25/25） and 92. 60% （25/27）, respectively, the two-year survival rates in observation group and control group were 92. 00% （23/25） and 74.07% （20/27）, respectively, there were statistically significant differences between the two groups （P〈0.05） . The incidence rate of Ⅲ degree adverse reactions was 16.00%, no Ⅳ degree adverse reaction and treatment-related death occurred. Conclusion Maintenance treatment via interferon-γcan prolong PFS and two-year survival rate of patients with middle and advanced ovarian cancer.

关 键 词：干扰素-Γ 维持治疗 卵巢癌 无进展生存期 

分 类 号：R737.31[医药卫生—肿瘤]